Betul Oran
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Betul Oran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06297629 · A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell TransplantationM.D. Anderson Cancer Center · withdrawn · Allogeneic Stem Cell Transplantation · principal investigator
- Ph2NCT04128501 · Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingM.D. Anderson Cancer Center · active not recruiting · Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia · principal investigator
- Ph2NCT02684162 · Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell TransplantM.D. Anderson Cancer Center · completed · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT02210078 · Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus InfectionM.D. Anderson Cancer Center · active not recruiting · Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm · principal investigator
- Ph2NCT02210065 · Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) ReactivationM.D. Anderson Cancer Center · completed · Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clonal Evolution and Immune Dysregulation in AML patients treated with Venetoclax and Azacitidine after Allogeneic Stem Cell TransplantationR21CA309007 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $421,685 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:54 UTC. The ranking covers the 200 most relevant of 52 PubMed records, and a shared surname and initials can bring in a namesake. All 52 on PubMed
- Cord-blood engraftment with ex vivo mesenchymal-cell coculture.N Engl J Med · 2012371 citationsRCR 10.3
- A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.Blood Adv · 2020194 citationsRCR 8.9
- Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Biol Blood Marrow Transplant · 2014183 citationsRCR 6.1
- 138 citationsRCR 7.6
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.Biol Blood Marrow Transplant · 2018136 citationsRCR 5.0
- 115 citationsRCR 3.5
- Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.Biol Blood Marrow Transplant · 2007103 citationsRCR 2.6
- 75 citationsRCR 2.9
- Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Lancet Haematol · 201975 citationsRCR 3.1
- Sydenham's chorea: a clinical follow-up of 65 patients.J Child Neurol · 200760 citationsRCR 2.0